The combination of hypercalcaemia, hypercalciuria, and nephrocalcinosis with and without renal impairment is rare in paediatric clinical practice. However, this constellation of findings has been reported in children with trisomy 21, but the absence of detailed nutritional data has failed to clarify the underlying pathogenesis. This report describes a 4 year old girl with trisomy 21 who was found coincidentally to have hypercalcaemia, hypercalciuria, nephrocalcinosis, and renal impairment in the absence of metabolic alkalosis, following a prolonged period of excessive calcium intake.

A 4 year old girl with trisomy 21 and symptomatic gastrooesophageal reflux was coincidentally found to have hypercalcaemia (3.35 mmol/litre) associated with an increased plasma urea (19.3 mmol/litre) and creatinine (144 µmol/litre) and normal plasma bicarbonate (22 mmol/litre) and phosphate (1.6 mmol/litre).

She was born at 33 weeks gestation, with evidence of intrapartum asphyxia requiring transient ventilatory and inotropic support. Follow up at age 4 months, while she was receiving standard infant milk formula, revealed a normal plasma creatinine (25 µmol/litre), calcium (2.32 mmol/litre), and renal ultrasound. A 99Technetium dimercaptosuccinic acid scan at 6 months was also normal.

Medical management comprising cimetidine, cisapride, and Nesterigel to thicken feeds was unsuccessful in controlling her vomiting and because of the persistent confirmed acid reflux, she was referred for fundoplication and gastrostomy insertion.

After the observation of hypercalcaemia, further investigations revealed normal concentrations of alkaline phosphatase (91 U/litre; normal range, 90–850), calcitonin (10 ng/litre; normal value, < 15), and angiotensin converting enzyme (39 U/litre; normal range, 0–88), in addition to normal thyroid function. Her parathyroid hormone (PTH) was suppressed at 1.1 pmol/litre (normal value, < 8) and the PTH related peptide was 0.8 pmol/litre (normal value, < 2.6). Plasma 25 hydroxycholecalciferol was raised at 133 nmol/litre (normal range, 25–125) and 1,25 dihydroxycholecalciferol was reduced at 0.44 pmol/litre (normal range, 0.8–2.6). Plasma 25 hydroxycholecalciferol was raised at 133 nmol/litre (normal range, 25–125) and 1,25 dihydroxycholecalciferol was reduced at 26 pmol/litre (normal range, 75–120). Chromosome analysis failed to show a deletion at 7q11.23 in 10 analyses, excluding William’s syndrome. The spot urine calcium to creatinine ratio was 2.03 mmol/mmol (normal value, < 1.1) and the urate to creatinine ratio was 0.35 mmol/mmol (normal value, < 1.5).

 Pronounced medullary nephrocalcinosis was seen on both abdominal ultrasound and x-ray. Wrist and hand x-ray demonstrated a delayed bone age but no features of hyperparathyroidism.

A detailed nutritional assessment (table 1) demonstrated a calcium intake before diagnosis of 22.7 mmol/day (recommended daily intake of calcium, 8.8 mmol/day), increasing to 24.7 mmol/day with gastrostomy feeding. However, it should be noted that most infants and children on “normal” diets consume significantly more than the recommended daily intake of calcium, and the regimen this child received was considered appropriate for a child with her history of failure to thrive.

Following the fundoplication there was resolution of the vomiting and all anti-reflux treatment was ceased. The hypercalcaemia and hypercalciuria resolved within three months of the introduction of a low calcium and sodium diet, with progressive improvement in renal function (table 1). At this point, an oral calcium loading test (1 g/M2) demonstrated an increase in the urinary calcium to creatinine ratio from 0.44 mmol/mmol at baseline to 1.07 mmol/mmol at four hours, with no change in plasma calcium.

The dietary calcium restriction was progressively relaxed and normalised by age 7.6 years. The plasma and urine calcium values have remained normal, with the most recent plasma creatinine being 72 µmol/litre (estimated glomerular filtration rate, 47/ml/min/1.73 m2). At the age of 8.8 years her PTH was 14.9, with normal concentrations of both 25 hydroxycholecalciferol and 1,25 dihydroxycholecalciferol.

### Table 1 Nutritional and biochemical data

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Feed</th>
<th>Feed volume ml/kg</th>
<th>Calcium intake (mmol)</th>
<th>Sodium intake (mmol)</th>
<th>Plasma calcium (mmol/l)</th>
<th>Plasma creatinine (mmol/l)</th>
<th>Urinary Ca/Creat (mmol/ mmol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.33</td>
<td>Cows’ milk</td>
<td>110</td>
<td>22.7 [8.8]</td>
<td>15.7 [13–27]</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>1.85</td>
<td>Nutrison Progress</td>
<td>186</td>
<td>24.7 [8.8]</td>
<td>21.7 [14–28]</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>4.4</td>
<td>Nutrison Progress</td>
<td>155</td>
<td>20.6 [8.8]</td>
<td>18.1 [14–28]</td>
<td>3.35</td>
<td>144</td>
<td>2.03</td>
</tr>
<tr>
<td>4.51</td>
<td>Locasol</td>
<td>109</td>
<td>8.6 [11.3]</td>
<td>18.7 [17–34]</td>
<td>3.0</td>
<td>108</td>
<td>1.08</td>
</tr>
<tr>
<td>4.7</td>
<td>Locasol Nutrison</td>
<td>96</td>
<td>2.1 [11.3]</td>
<td>13.9 [21–42]</td>
<td>2.49</td>
<td>94</td>
<td>0.44</td>
</tr>
<tr>
<td>5.5</td>
<td>Locasol Nutrison</td>
<td>85</td>
<td>5.5 [11.3]</td>
<td>18.2 [21–42]</td>
<td>2.63</td>
<td>88</td>
<td>0.22</td>
</tr>
<tr>
<td>6.0</td>
<td>Locasol</td>
<td>96</td>
<td>10.1 [11.3]</td>
<td>13.9 [21–42]</td>
<td>2.59</td>
<td>92</td>
<td>0.05</td>
</tr>
<tr>
<td>7.8</td>
<td>Mixed diet</td>
<td>14.6</td>
<td>13.8</td>
<td>22.3 [21–42]</td>
<td>2.54</td>
<td>72</td>
<td>&lt;0.03</td>
</tr>
</tbody>
</table>

Figures in parenthesis for calcium and sodium intake indicate recommended daily nutritional intakes (RDI).

Ca/Creat, calcium/creatinine ratio; N/A, not available.
The diagnosis of classic milk-alkali syndrome is unlikely in our patient but had no antacid treatment prescribed. The diagnosis of classic milk-alkali syndrome is unlikely in our patient because alkalosis compromised alkaline phosphatase. Finally hypercalciuria is absent in most cases of milk-alkali syndrome because alkalosis compromises urinary calcium excretion.

The findings of hypercalcaemia, hypercalciuria, and nephrocalcinosis are rare in childhood and generally occur in the context of William’s syndrome, thyrotoxicosis, hyperparathyroidism, sarcoidosis, certain malignancies, vitamin A and D excess, diuretic abuse, or prolonged immobilisation.

There are a small number of reports of hypercalcaemia in Down’s syndrome, with the findings in these cases attributed to excessive calcium intake. However, evidence for this hypothesis to date is absent and alternative contributory factors such as antacid administration have been proposed.

Our patient was known to consume large volumes of milk but had no antacid treatment prescribed. The diagnosis of classic milk-alkali syndrome is unlikely in our patient; first, because of the absence of metabolic alkalosis, although this may be attenuated by impaired renal function and, second, because of the absence of other associated biochemical abnormalities, including hypokalaemia, hyperphosphataemia, and raised alkaline phosphatase. Finally hypercalciuria is absent in most cases of milk-alkali syndrome because alkalosis compromises urinary calcium excretion.

“The diagnosis of classic milk-alkali syndrome is unlikely in our patient”

**DISCUSSION**

Intestinal calcium absorption occurs through both a passive and an active vitamin D dependent mechanism. Increased calcium ingestion results in a compensatory decrease in vitamin D mediated absorption and an increase in faecal calcium excretion. In our patient, there was evidence of suppression of 1,25 vitamin D3 and increased urinary calcium excretion following an oral calcium load. In healthy children, calcium restriction before a calcium loading test resulted in a slightly higher urinary calcium to creatinine ratio compared with those not restricted beforehand, but not to the extent seen in our patient. These findings, along with the biochemical and clinical improvement following dietary calcium restriction, suggest a possible genetic predisposition to enhanced calcium absorption via the passive route in trisomy 21, despite the presence of hypercalcaemia, and suggest that this is an example of “milk drinker’s” hypercalcaemia.

**Authors’ affiliations**

I J Ramoge, A Durkan, K Walker, T J Beattie, The Royal Hospital for Sick Children, Glasgow G3 8SJ, UK

Correspondence to: Dr T J Beattie, The Royal Hospital for Sick Children, Glasgow G3 8SJ, UK; jim.beattie@yorkhill.scot.nhs.uk

Accepted for publication 13 December 2001

**REFERENCES**


Hypercalcaemia in association with trisomy 21 (Down's syndrome)

I J Ramage, A Durkan, K Walker and T J Beattie

doi:

Updated information and services can be found at:
[http://jcp.bmj.com/content/55/7/543](http://jcp.bmj.com/content/55/7/543)

These include:

**References**
This article cites 4 articles, 1 of which you can access for free at:
[http://jcp.bmj.com/content/55/7/543#BIBL](http://jcp.bmj.com/content/55/7/543#BIBL)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)